Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their CombinationX. Cynthia, Lisa A. Carey, Vera J. Suman et al.|JAMA Oncology|2024Cited by 20
Building a queer- and trans-inclusive microbiology conferenceRachel Gregor, Heema Kumari Nilesh Vyas, Daniel Muratore et al.|mSystems|2023Cited by 13
Building a Queer- and Trans-Inclusive Microbiology ConferenceRachel Gregor, JL Weissman, Julie Johnston et al.|Unknown|2023Cited by 2